DJIA 18,135.72 38.82 0.21%
NASDAQ 4,982.81 0.00 0.00%
S&P 500 2,101.04 2.51 0.12%
market minute promo

company name or ticker
Company Photos
(Click to zoom)

Get Out Of Swiss Stocks Now: Barclays

CM, CS And SPG, 3 Financial Stocks Pushing The Sector Lower

SolarCity to Launch $200M Financing Facility under MyPower - Analyst Blog

6 Stocks Riding the Swiss Franc Surge - Stocks in the News

Here’s a Reason Credit Suisse (CS) Stock Is Higher Today

Macy's A Potential Buy Despite All Odds

Swiss ADRs Gain Big As Swiss National Bank Surprises With Currency Revaluation

Buy These Five Internet Stocks in 2015, Says Credit Suisse

10 Investment Banks that Stand to Lose the Most from Oil's Decline

Diving Deeper into Biogen's Lingo Results

Biogen's nerve repair drug failed to clear some key hurdles in its clinical trial against an eye disease. But the company highlighted positive data that shows the drug could have potential in its much more important target, multiple sclerosis.
See More Articles...